In this feature article by AIS Health, Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, shares her predictions on how the lobbying landscape will shift in the coming years. “It’s unsurprising to see providers and the pharmaceutical industry take an increasing role in government affairs over time, given how the government’s regulation over their business has intensified over the years,” she states. Read more about Lindsay’s insights and perspective here.